Notice of Closed Meeting, 16371 [2021-06370]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 58 / Monday, March 29, 2021 / Notices
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–06368 Filed 3–26–21; 8:45 am]
[FR Doc. 2021–06370 Filed 3–26–21; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Medicare & Medicaid
Services
Notice of Closed Meeting
[CMS–3408–N]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA OH–21–007, Continuation and
Expansion of the National
Mesothelioma Virtual Bank for
Translational Research.
Date: May 11, 2021.
Time: 1:00 p.m.–3:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Laurel Garrison, M.P.H., Scientific
Review Official, National Institute for
Occupational Safety and Health, CDC,
5555 Ridge Avenue, Cincinnati, Ohio
45213, Telephone (513) 533–8324;
LGarrison@cdc.gov.
CLIA Program; Announcement of the
Re-Approval of the College of
American Pathologists (CAP) as an
Accreditation Organization Under the
Clinical Laboratory Improvement
Amendments of 1988
VerDate Sep<11>2014
17:20 Mar 26, 2021
Jkt 253001
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces the
application of the College of American
Pathologists (CAP) for approval as an
accreditation organization for clinical
laboratories under the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) program. We have
determined that the CAP meets or
exceeds the applicable CLIA
requirements. In this notice, we
announce the approval and grant CAP
deeming authority for a period of 6
years.
DATES: This notice is effective from
March 27, 2021 until March 26, 2027.
FOR FURTHER INFORMATION CONTACT:
Cindy Flacks, 410–786–6520.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background and Legislative
Authority
On October 31, 1988, the Congress
enacted the Clinical Laboratory
Improvement Amendments of 1988
(CLIA) (Pub. L. 100–578). CLIA
amended section 353 of the Public
Health Service Act. We issued a final
rule implementing the accreditation
provisions of CLIA on July 31, 1992 (57
FR 33992). Under those provisions, we
may grant deeming authority to an
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
16371
accreditation organization if its
requirements for laboratories accredited
under its program are equal to or more
stringent than the applicable CLIA
program requirements in 42 CFR part
493 (Laboratory Requirements). Subpart
E of part 493 (Accreditation by a Private,
Nonprofit Accreditation Organization or
Exemption Under an Approved State
Laboratory Program) specifies the
requirements an accreditation
organization must meet to be approved
by CMS as an accreditation organization
under CLIA.
II. Notice of Approval of CAP as an
Accreditation Organization
In this notice, we approve the College
of American Pathologists (CAP) as an
organization that may accredit
laboratories for purposes of establishing
their compliance with CLIA
requirements in all specialties and
subspecialties. We have examined the
initial CAP application and all
subsequent submissions to determine its
accreditation program’s equivalency
with the requirements for approval of an
accreditation organization under
subpart E of part 493. We have
determined that the CAP meets or
exceeds the applicable CLIA
requirements. We have also determined
that the CAP will ensure that its
accredited laboratories will meet or
exceed the applicable requirements in
subparts H, I, J, K, M, Q, and the
applicable sections of R. Therefore, we
grant the CAP approval as an
accreditation organization under
subpart E of part 493, for the period
stated in the DATES section of this notice
for all specialties and subspecialties
under CLIA. As a result of this
determination, any laboratory that is
accredited by the CAP during the time
period stated in the DATES section of this
notice will be deemed to meet the CLIA
requirements for the listed specialties
and subspecialties, and therefore, will
generally not be subject to routine
inspections by a state survey agency to
determine its compliance with CLIA
requirements. The accredited laboratory,
however, is subject to validation and
complaint investigation surveys
performed by CMS, or its agent(s).
III. Evaluation of the CAP Request for
Approval as an Accreditation
Organization Under CLIA
The following describes the process
used to determine that the CAP
accreditation program meets the
necessary requirements to be approved
by CMS and that, as such, we may
approve the CAP as an accreditation
program with deeming authority under
the CLIA program. The CAP formally
E:\FR\FM\29MRN1.SGM
29MRN1
]]>Agencies
[Federal Register Volume 86, Number 58 (Monday, March 29, 2021)]
[Notices]
[Page 16371]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06370]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--RFA OH-21-007, Continuation and
Expansion of the National Mesothelioma Virtual Bank for Translational
Research.
Date: May 11, 2021.
Time: 1:00 p.m.-3:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Laurel Garrison, M.P.H.,
Scientific Review Official, National Institute for Occupational Safety
and Health, CDC, 5555 Ridge Avenue, Cincinnati, Ohio 45213, Telephone
(513) 533-8324; [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-06370 Filed 3-26-21; 8:45 am]
BILLING CODE 4163-18-P
